Anna Goldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9268838/publications.pdf Version: 2024-02-01



ANNA COLDMAN

#	Article	IF	CITATIONS
1	Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1715-1744.	3.6	1,050
2	Testosterone dose-response relationships in healthy young men. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E1172-E1181.	3.5	767
3	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	27.0	675
4	Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 678-688.	3.6	492
5	Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 914-919.	3.6	310
6	Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 146-159.	2.8	272
7	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Internal Medicine, 2017, 177, 471.	5.1	241
8	A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. Endocrine Reviews, 2017, 38, 302-324.	20.1	231
9	Testosterone Dose-Dependently Increases Maximal Voluntary Strength and Leg Power, but Does Not Affect Fatigability or Specific Tension. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1478-1485.	3.6	221
10	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	5.1	180
11	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	20.1	173
12	Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell, 2013, 12, 280-291.	6.7	147
13	Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production. JAMA - Journal of the American Medical Association, 2012, 307, 931-9.	7.4	131
14	The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 87-95.	3.6	114
15	Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3096-3104.	3.6	110
16	The Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1745-1754.	3.6	107
17	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	1.6	98
18	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 681-688.	3.6	79

Anna Goldman

#	Article	IF	CITATIONS
19	Tests of Muscle Strength and Physical Function: Reliability and Discrimination of Performance in Younger and Older Men and Older Men with Mobility Limitations. Journal of the American Geriatrics Society, 2008, 56, 2118-2123.	2.6	71
20	Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 991-1004.	3.6	60
21	Adverse health effects of androgen use. Molecular and Cellular Endocrinology, 2018, 464, 46-55.	3.2	28
22	Testosterone Doseâ€Dependency of Sexual and Nonsexual Behaviors in The Gonadotropinâ€Releasing Hormone Antagonistâ€Treated Male Rat. Journal of Andrology, 1989, 10, 167-173.	2.0	20
23	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246.	3.6	20
24	The Implications of Reproductive Aging for the Health, Vitality, and Economic Welfare of Human Societies. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3821-3825.	3.6	16
25	Allosterically Coupled Multisite Binding of Testosterone to Human Serum Albumin. Endocrinology, 2021, 162, .	2.8	14
26	A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2171-2186.	3.6	14
27	Fertility Considerations in Adolescent Klinefelter Syndrome: Current Practice Patterns. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1918-e1920.	3.6	12
28	Relation of Testosterone, Dihydrotestosterone, and Estradiol With Changes in Outcomes Measures in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1257-1269.	3.6	8
29	Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2142-2149.	3.6	4
30	Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles. Journal of the Endocrine Society, 2022, 6, .	0.2	2
31	T4DM Trial and its T4Bone Substudy Shed Further Light on Effects of Testosterone Treatment in Middle-Aged and Older Men. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3269-e3271.	3.6	1
32	Optimized Use of the Electronic Health Record and Other Clinical Resources to Enhance the Management of Hypogonadal Men. Endocrinology and Metabolism Clinics of North America, 2022, 51, 217-228.	3.2	1